News

Cynbiose and VirNext have joined forces to offer a unique and innovative preclinical package of services for the evaluation of drugs, vaccines and antibodies candidates against (re)-emergent respiratory viruses, from in vitro screening to in vivo efficacy models of infections, including large animals. On the basis of a public-private partnership initiated in 2017, we have contributed to the evaluation of hundreds of candidates for respiratory viruses, including SARSCoV2 variants, cell lines, rec...

This is a major first step in our collaborative project OZONE, accredited by the Lyonbiopôle healthcare cluster and the TECHTERA cluster for the textile industry in France, and winner of the R&D booster 2021 call for projects, supported by the Auvergne-Rhône-Alpes Regional Innovation Fund and Bpifrance. The second phase of the programme will be implemented in our BSL-2 and BSL-3 laboratories within Lyonbiopôle's Centre Innovation. This collaborative academic and industrial project, in...

We report the antiviral activity of 95 single compounds from the Medicines for Malaria Venture (MVV) and the Calibr ReFRAME drug libraries and 30 combinations with the orally bioactive RdRp inhibitor molnupiravir against SARSCoV2. We performed this standardized medium-throughput screening by using the physiologically relevant reconstituted human airway epithelia MucilAir model (Epithelix), facilitating both reproducibility of results and a clear distinction between antiviral and toxic effects of...

Created 3 months ago with the support of Lyon Ingénierie Projet and EZUS Lyon, VirexpR is specialized in the generation of atmospheres contaminated by respiratory viruses or complex mixtures of infectious pathogens in test benches dedicated to the experimental evaluation of air treatment and respiratory protection technologies and devices. This alliance with the TERA Group, a company listed on the stock exchange (Euronext Growth) and internationally recognized as a major player in real-time air...

Innobiovir is dedicated to research, services and training in the bioproduction and pharmaceutical formulation of viral antigens and biopharmaceuticals. Innobiovir is an alliance between our Virnext Technological Research platform, the VirPath laboratory, the Laboratoire d'Automatique de GEnie des Procédés et de génie Pharmaceutique (LAGEPP, CNRS - UCBL1), the Institut de Pharmacie Industrielle de Lyon (IPIL - ISPB) and the Biological Engineering department of the IUT Lyon 1 (UCBL1). The plat...

Virnext is very proud of its spin-off Vaxxel, which has raised €1.2m to support the development of its bivalent intranasal vaccine candidate against bronchiolitis and severe viral pneumonia. This is excellent recognition of the METAVAC® polyvalent viral vaccine platform developed by VirPath laboratory and Technology Research platform Virnext in partnership with Dr Guy Boivin's team (Centre de recherche du CHU de Québec-Université Laval) and transferred to Vaxxel for the pharmaceutical devel...

With the support of Lyon Ingénierie Projet and EZUS Lyon, the subsidiaries of Université Claude Bernard Lyon 1, this new service-oriented spin-off proposes new innovative technological offers and a wider range of R&D services in the field of Indoor Air Quality (IAQ). VirexpR is specialized in the generation of atmospheres contaminated by viruses and complex mixtures of infectious pathogens in test benches dedicated to the experimental evaluation of air treatment and analysis technologie...

VirNext est très fière d'être lauréate du prix de l'innovation 2021 #Contaminexpo remis par Bastien Cany et Stéphane ORTU. Nous remercions l'Aspec Association, Salles Propres et les membres du jury pour leur confiance et la reconnaissance de nos savoir-faire dans la génération d'atmosphères hautement contaminées par des virus respiratoires, incluant le #SARSCOV2, dédiés à l'évaluation des technologies et dispositifs épurateur d'air. Un grand merci à toutes les équipes de l'Asp...

Notre plateforme VirNext était présente du 12 au 15 octobre au salon #Pollutec à Lyon Eurexpo afin d’échanger sur nos savoir-faire uniques dans l’évaluation des technologies de purification de l’air contre le virus SARS-CoV-2 et autres virus respiratoires pathogènes....

Notre plateforme VirNext est toujours mobilisée dans la lutte contre la Covid-19 en évaluant expérimentalement différentes technologies de purification de l’air en partenariat avec Lyonbiopôle #CentreInnovation et dans la dynamique insufflée par la Région Auvergne-Rhône-Alpes. VirNext présentera ses expertises et services pour l’évaluation de performance des technologies de décontamination de l’air intérieur contre les virus respiratoires au salon #ContaminExpo, le rend...